Sight Sciences (Sight Sciences) Debt-to-Equity : 0.32 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sight Sciences Debt-to-Equity?

Sight Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.51 Mil. Sight Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $34.50 Mil. Sight Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $109.21 Mil. Sight Sciences's debt to equity for the quarter that ended in Mar. 2024 was 0.32.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sight Sciences's Debt-to-Equity or its related term are showing as below:

SGHT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.37 Med: 0.18 Max: 0.32
Current: 0.32

During the past 6 years, the highest Debt-to-Equity Ratio of Sight Sciences was 0.32. The lowest was -0.37. And the median was 0.18.

SGHT's Debt-to-Equity is ranked worse than
58.72% of 705 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs SGHT: 0.32

Sight Sciences Debt-to-Equity Historical Data

The historical data trend for Sight Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sight Sciences Debt-to-Equity Chart

Sight Sciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.26

-0.37

0.15

0.22

0.30

Sight Sciences Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial														0.24	0.26	0.27	0.30	0.32

Competitive Comparison of Sight Sciences's Debt-to-Equity

For the Medical Devices subindustry, Sight Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sight Sciences's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sight Sciences's Debt-to-Equity falls into.

Sight Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sight Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.792	+	32.622)	/	120.215
	=	0.29

Sight Sciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.509	+	34.499)	/	109.209
	=	0.32

Sight Sciences (NAS:SGHT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sight Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sight Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sight Sciences (Sight Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sight Sciences Inc (NAS:SGHT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.sightsciences.com

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Executives

Jeremy B. Hayden	officer: Chief Legal Officer	2 MUSICK, 2 MUSICK, IRVINE CA 92618
Sam Boong Park	officer: Chief Operating Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Paul Badawi	director, 10 percent owner, officer: President and CEO	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
David Badawi	director, officer: Chief Technology Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
D1 Capital Partners L.p.	10 percent owner	9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Staffan Encrantz	director	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Matthew Link	officer: Chief Commercial Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Catherine Mazzacco	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Alison Bauerlein	officer: See remarks	326 BOLLAY DRIVE, GOLETA CA 93117
James Rodberg	officer: See Remarks	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK CA 94025
Tamara Fountain	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Brenda Jane Larsen-becker	director	C/O SIGHT SCIENCES, INC., 3000 SAND HILL ROAD, BUILDING 3, STE 105, MENLO PARK CA 94025
Jesse Selnick	officer: Chief Financial Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Daniel S. Sundheim	10 percent owner	C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Erica J. Rogers	director	C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089